FDA approves at-home use of Igalmi for agitation; deuterated psilocin meets phase 3 depression end point; lithium suicide evidence less certain

Two armchairs angled toward each other with a small round side table and a lamp between them.

The Food and Drug Administration (FDA) approved Teva's Igalmi sublingual dexmedetomidine for at-home use for agitation in schizophrenia and bipolar disorder, which Teva said makes it the first such treatment.

Helus Pharma reported that deuterated psilocin met its phase 3 primary end point in adjunctive treatment of depression. An umbrella review found lithium's effect on suicide less certain than earlier syntheses suggested.

The weekly innovation roundup for psychiatry, published every Sunday for the week before; every item links to its sources. Latest psychiatry news · All specialties

Latest news

Tagged psychiatry, from the daily briefing

  1. Randomized trial in 151 adults with type 1 diabetes tests adding a diabetes-educated psychologist to usual care
  2. Meta-analysis of 3,675 participants finds lithium's suicide estimate favors lithium but includes the null
  3. Helus says its modified psilocybin met key goals in a phase 3 trial as adjunctive treatment for major depression

See all the latest news